SAUNDERTON, ENGLAND — May 27, 2002 —
The UK’s first skin patch to offer strong pain relief (DurogesicTM – transdermal fentanyl) – has received approval from UK regulators allowing its use for the first time to treat chronic
(ongoing or continued) intractable pain such as arthritis and back pain.
Chronic pain affects over four million people in the UK1, and has a huge economic impact2 as well as a major impact on a person’s quality of life.
Studies have shown that Durogesic improves the quality of life for people who have suffered for many years with hard-to-treat chronic pain, such as back pain.3,4 According to a new research survey among UK GPs, doctors estimate that fewer than half of their patients with chronic pain receive optimal pain control5 despite the fact that it is one of the most common reasons for seeing a doctor.
6 “Chronic pain is often difficult to treat and we need as many treatment options as possible. The approval of Durogesic for the management of chronic pain will usefully increase the available options in the treatment of this debilitating, demoralising and distressing condition” commented Dr Catherine Stannard, a specialist in pain medicine from the Frenchay Hospital in Bristol, who co-authored the research.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!